View More Recent Stories
-
Valeant Pharma (VRX) TRx Continues Gains in Week 3 of Walgreens Deal - Evecore ISI
-
Valeant Pharma (VRX) IMS Script Data Remains Strong in Week 2 Post-Walgreens - Evercore ISI
-
'No Blatant Lies' Seen from Valeant (VRX) CEO/CFO Exchange and Philidor Scripts Were Not Just Smoke and Mirrors - Evercore ISI
-
Evercore ISI Follows Up on Valeant Pharma (VRX) Response to Questions
-
Did Price or Volume Drive Valeant Pharma (VRX) Growth?; Evercore ISI's Raffat Digs In
-
Valeant names interim CEO; timing of Pearson's return unknown
-
Valeant (VRX) CEO Medical Leave Not a 'Graceful Exit' - Evercore ISI's Raffat
-
Valeant's (VRX) Walgreens Deal a 'Big Credibility Boost' - Evercore ISI's Raffat
-
Valeant Pharma (VRX) on Watch as Top Analyst Holds Conf Call
-
Teva Pharma (TEVA) AdCom 'Not Gong Well' - Evecore ISI's Raffat
-
Valeant Pharma (VRX) on Watch as Evercore ISI's Raffat Highlights Court Documents Refuting Short Allegation
-
Evercore ISI's Raffat Addresses Bronte Capital Blog Post on Valeant Pharma (VRX)
-
Philidor has dropped its litigation against R&O (VRX) - Evercore ISI's Raffat
-
Valeant Pharma (VRX) Products are Selling Ex-Philidor - Evercore ISI's Raffat
-
New Treasury Guidelines on Inversion May Not Apply to Allergan (AGN)/Pfizer (PFE) - Evercore ISI's Raffat
-
Medicines (MDCO)/Alnylam (ALNY) to Present Phase 1 Data on siRNA-based PCSK9 Today
-
Valeant Pharma (VRX) Issues Dear Doctor Letter; Philidor Issues Release - Evercore ISI
-
Evercore ISI's Raffat Provides Thoughts on Valeant Pharma (VRX)
-
Valeant Pharma (VRX) Halts the Bloodletting Following Conference Call

